Pharmaceutical companies by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Roivant Sciences leads the 50 pharmaceutical companies ranked by P/S ratio, at 3370, ahead of Dianthus Therapeutics (2367) and Protagonist Therapeutics (178). Figures as of 18 Nov 2026, 19:33 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 50
- First
- Roivant Sciences3370
- Median
- 6.9
- Combined market value
- TRY 255.17T
- Countries
- 10
- Not ranked
- 11no P/S ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/S ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Roivant SciencesROIV · Health Care | 3370 | TRY 1.4T | TRY 1,937.60 | 0.75% down | 90% up | ||
| 2 | Dianthus TherapeuticsDNTH · Health Care | 2367 | TRY 243.1B | TRY 4,316.48 | 1.60% down | 113% up | ||
| 3 | Protagonist TherapeuticsPTGX · Health Care | 178 | TRY 413B | TRY 6,327.21 | 0.63% up | 46% up | ||
| 4 | CytokineticsCYTK · Health Care | 81.0 | TRY 359.5B | TRY 2,580.61 | 0.93% down | 20% down | ||
| 5 | Rhythm PharmaceuticalsRYTM · Health Care | 43.9 | TRY 419.9B | TRY 6,056.90 | 2.99% up | 13% up | ||
| 6 | InsmedINSM · Health Care | 43.5 | TRY 1.33T | TRY 6,058.91 | 1.41% down | 40% down | ||
| 7 | BridgeBio PharmaBBIO · Health Care | 30.1 | TRY 763.2B | TRY 3,918.07 | 1.16% up | 17% up | ||
| 8 | Ligand PharmaceuticalsLGND · Health Care | 22.3 | TRY 301.9B | TRY 15,092.81 | 1.86% up | 43% up | ||
| 9 | Ascendis PharmaASND · Health Care | 22.1 | TRY 892.3B | TRY 13,602.55 | 0.54% down | 28% up | ||
| 10 | Eli LillyLLY · Health Care | 18.9 | TRY 62.15T | TRY 69,777.85 | 2.26% down | 35% up | ||
| 11 | Royalty PharmaRPRX · Health Care | 16.8 | TRY 2.01T | TRY 3,497.21 | 0.97% up | 78% up | ||
| 12 | TG TherapeuticsTGTX · Health Care | 16.1 | TRY 500.5B | TRY 3,311.62 | 4.71% up | 107% up | ||
| 13 | Mirum PharmaceuticalsMIRM · Health Care | 11.5 | TRY 303.4B | TRY 4,647.32 | 0.22% up | 31% up | ||
| 14 | Vertex PharmaceuticalsVRTX · Health Care | 11.4 | TRY 6.87T | TRY 27,108.77 | 0.62% up | 27% up | ||
| 15 | Axsome TherapeuticsAXSM · Health Care | 11.1 | TRY 356B | TRY 6,768.49 | 1.28% down | 7% down | ||
| 16 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 11.0 | TRY 375.8B | TRY 4,782.48 | 0.29% down | 126% up | ||
| 17 | Travere TherapeuticsTVTX · Health Care | 9.9 | TRY 244.5B | TRY 2,547.07 | 1.16% down | 44% up | ||
| 18 | Madrigal PharmaceuticalsMDGL · Health Care | 9.7 | TRY 470.6B | TRY 20,258.32 | 4.81% down | 24% down | ||
| 19 | Corcept TherapeuticsCORT · Health Care | 9.7 | TRY 373.6B | TRY 3,413.37 | 3.41% down | 8% down | ||
| 20 | BeOne MedicinesONC · Health Care | 8.6 | TRY 2.33T | TRY 20,382.13 | 2.20% down | 17% up | ||
| 21 | GenmabGMAB · Health Care | 8.5 | TRY 1.59T | TRY 2,586.66 | 1.29% down | 70% up | ||
| 22 | AbbVieABBV · Health Care | 8.3 | TRY 25.46T | TRY 14,402.15 | 2.47% down | 26% up | ||
| 23 | United TherapeuticsUTHR · Health Care | 7.7 | TRY 1.24T | TRY 29,195.65 | 0.89% down | 23% up | ||
| 24 | Arrowhead PharmaceuticalsARWR · Health Care | 7.4 | TRY 308.1B | TRY 2,179.42 | 0.52% up | 10% up | ||
| 25 | Johnson & JohnsonJNJ · Health Care | 7.0 | TRY 33.21T | TRY 13,794.69 | 1.86% down | 38% up | ||
| 26 | Regeneron PharmaceuticalsREGN · Health Care | 6.8 | TRY 4.93T | TRY 47,645.73 | 1.36% down | 36% up | ||
| 27 | Alnylam PharmaceuticalsALNY · Health Care | 5.4 | TRY 1.01T | TRY 7,530.52 | 4.59% down | 66% down | ||
| 28 | NovartisNVS · Health Care | 5.4 | TRY 14.77T | TRY 7,821.01 | 2.55% down | 25% up | ||
| 29 | AlkermesALKS · Health Care | 5.3 | TRY 393.1B | TRY 2,339.04 | 2.05% up | 58% up | ||
| 30 | Merck & CoMRK · Health Care | 5.2 | TRY 17.07T | TRY 6,925.08 | 4.22% down | 51% up | ||
| 31 | Ionis PharmaceuticalsIONS · Health Care | 4.9 | TRY 232.2B | TRY 1,394.20 | 2.54% up | 64% down | ||
| 32 | AstraZenecaAZN · Health Care | 4.7 | TRY 13.96T | TRY 9,003.14 | 2.06% down | 2% up | ||
| 33 | Abbott LaboratoriesABT · Health Care | 4.1 | TRY 9.13T | TRY 5,270.66 | 0.19% down | 17% down | ||
| 34 | Novo NordiskNVO · Health Care | 3.8 | TRY 8.76T | TRY 1,987.28 | 3.18% down | 17% down | ||
| 35 | Jazz PharmaceuticalsJAZZ · Health Care | 3.7 | TRY 795.6B | TRY 12,394.19 | 2.10% up | 37% up | ||
| 36 | ZoetisZTS · Health Care | 3.7 | TRY 1.75T | TRY 4,305.82 | 2.27% up | 29% down | ||
| 37 | BioMarin PharmaceuticalBMRN · Health Care | 3.7 | TRY 595.2B | TRY 3,072.83 | 4.14% up | 11% up | ||
| 38 | Dr. Reddy's LaboratoriesRDY · Health Care | 3.5 | TRY 630B | TRY 755.73 | 1.32% up | 5% up | ||
| 39 | Legend BiotechLEGN · Health Care | 3.0 | TRY 158.1B | TRY 814.98 | 0.31% up | 42% down | ||
| 40 | PTC TherapeuticsPTCT · Health Care | 2.9 | TRY 252.8B | TRY 3,025.93 | 0.60% down | 20% down | ||
| 41 | Teva Pharmaceutical IndustriesTEVA · Health Care | 2.8 | TRY 2.48T | TRY 2,124.70 | 1.15% down | 74% up | ||
| 42 | Elanco Animal HealthELAN · Health Care | 2.8 | TRY 676.8B | TRY 1,354.10 | 3.87% up | 20% up | ||
| 43 | PfizerPFE · Health Care | 2.6 | TRY 8.06T | TRY 1,414.24 | 1.50% down | 14% up | ||
| 44 | Bristol-Myers SquibbBMY · Health Care | 2.5 | TRY 6.14T | TRY 3,005.25 | 2.87% down | 34% up | ||
| 45 | Amneal PharmaceuticalsAMRX · Health Care | 2.5 | TRY 383.2B | TRY 1,099.92 | 3.27% up | 83% up | ||
| 46 | Takeda PharmaceuticalTAK · Health Care | 2.4 | TRY 3.43T | TRY 1,073.20 | 1.66% down | 54% up | ||
| 47 | SanofiSNY · Health Care | 2.3 | TRY 5.72T | TRY 2,380.14 | 0.70% down | 4% down | ||
| 48 | GSKGSK · Health Care | 2.2 | TRY 4.91T | TRY 2,451.25 | 1.29% down | 6% up | ||
| 49 | ViatrisVTRS · Health Care | 1.7 | TRY 1.19T | TRY 1,038.14 | 0.66% up | 96% up | ||
| 50 | GrifolsGRFS · Health Care | 0.7 | TRY 289B | TRY 424.70 | 2.42% down | 1% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 50.4321 TRY). 11 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/S ratio?
Roivant Sciences (3370), Dianthus Therapeutics (2367) and Protagonist Therapeutics (178) are the top three of the 50 pharmaceutical companies ranked by P/S ratio as of 18 Nov 2026, 19:33 UTC.
How many pharmaceutical companies are in this ranking?
50 are ranked by P/S ratio. 11 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 50 pharmaceutical companies ranked by P/S ratio have a combined market value of TRY 255.17T as of 18 Nov 2026, 19:33 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/S ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.